Navigation Links
NIH selects LIAI for major study on allergy molecular causes and possible treatments
Date:11/13/2007

ounts for one-quarter of all emergency room visits in the U.S. each year.

LIAI researchers will identify the specific allergy epitopes that cause T cells to launch an attack against the allergens. Epitopes are tiny sites on a protein or other molecule that instigate a T cell response. This opens the possibility of developing therapies around those epitopes, Grey said. There have already been some clinical trials which are showing promise with the approach of treating patients with allergy-related epitopes. The information were developing will provide the clinical community with the ability to try this approach with a wide variety of allergic diseases.

Currently, many allergy sufferers receive desensitization treatments, whereby the patient is given increasing doses of the substance causing allergy or allergen over a long period of time in order to develop immune tolerance to the allergen. The approach can be problematic because patients already have antibodies to the allergens, which can cause reactions, and because it is also a very lengthy process. The idea behind the epitope-based therapies is that patients could be given small pieces or epitopes from the allergen that would be able to induce immune tolerance, without instigating an antibody reaction, Sette explained. If this proves true, it could produce the same effects as the current desensitization therapies, but in a much shorter period of time, and without the allergic side effects. You would be desensitizing the cells (with the allergy epitopes), rather than activating them, he added.

Another important aspect of the research is analyzing the effects of regulatory T cells in the allergy process. This T cell type, which has only been discovered in the last decade, appears to suppress T cell reactions to allergens, rather than cause them. We are hoping to find specific epitopes that activate these regulatory T cells, said John Sidney, project co-investigator. If so, we mi
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution
2. Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution
3. deCODE discovers cause of major subtype of glaucoma
4. Bleeding, not inflammation, is major cause of early lung infection death
5. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
6. Leading experts cite poor health and nutrition as major barrier to education in developing world
7. Majority of Americans want local action on global warming, says poll
8. How schizophrenia develops: Major clues discovered
9. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. A study by the MUHC and McGill University opens a new door to understanding cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)PHILADELPHIA Mexican-American adolescents exposed to cigarette smoking scenes in movies are more likely to pick up the habit themselves, and this may be part of the acculturation process associated w
(Date:12/2/2009)PHILADELPHIA Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researc
(Date:12/2/2009)Recalls of ground beef, peanut butter, and other foods have done more than raise public awareness and concern about food safety. They also are quietly fueling a boom in the market for food testing equ
Breaking Biology News(10 mins):Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 1Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 1NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 3Burnout and mental distress strongly related to errors by US surgeons 61962 1Burnout and mental distress strongly related to errors by US surgeons 61962 2
...National Institutes of Health (NIH) has awarded $4...search projects that could have an extraordinarily...grants, from a new program called EUREKA (for Exce...e Acceleration), targets investigators who are tes...ing major methodological or technical advances. E...
...rs for the detection of diseases including cancer ...ne this week in Cell Research . The findings pave...ic tool. , miRNAs are a class of naturally occurr...th cancer development. Recent studies reporting in...ic cancers were unable to rule out the possibility...
... released outside of their native ranges to contro...found that through complex community interactions ...ence of an introduced fly may exacerbate the effec...The authors report their results in the September ... Spotted knapweed, a flowering plant native to Eu...
Other Biology News:NYU Cancer Institute researcher among first NIH EUREKA award recipients 2Biocontrol insect exacerbates invasive weed 2Biocontrol insect exacerbates invasive weed 3
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
..., March 12 Micromet, Inc. (Nasdaq: MITI ), a bi...ary antibodies for the treatment of cancer, inflam...at it is regaining from its partner MedImmune the ...antibody candidate, blinatumomab, also known as MT...linical trial with blinatumomab for the treatment ...
... 12 Albert Liou, Corporate Vice President and Gen...national Corporation (Nasdaq: PRXL ), a leading ...resent "The True Value of Incorporating Asia into ...Medical Asia 2009 conference, to be held March 16 ...onvention & Exhibition Centre in Singapore. Mr...
...nds to acquire all outstanding shares of Genentech...nd early development to operate as an independent ...rters of combined U.S. commercial operations; Gene...novation will be enhanced through a diversity of r..., partnerships and other key assets , , -- Transa...
Other Biology Technology:Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 2PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 3PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 2Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 3Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 5Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 6Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 7
...Flow Perm/Wash Buffer I can be used in intracellul...ling proteins to permeabilize cells and to serve a...e saponin-mediated cell permeabilization is a reve...in the presence of saponin during intracellular st...
Mouse Anti-Human PREB Polyclonal Antibody, Unconjugated from Abnova Corporation
Mouse Anti-Human ACTN4 Monoclonal Antibody, Unconjugated, Clone 4D10 from Abnova Corporation
...iendly Eppendorf Thermomixer R offers maximum appl...equire shaking, heating, and cooling. Its active h...pplication and temperature control ranges. Five di...4 micro test tubes, are available for: 0.5 ml, 1.5...
Biology Products: